论文信息 - Paroxetine, Panorama and user reporting of ADRs: Consumer intelligence matters in clinical practice and post-marketing drug surveillance

Paroxetine, Panorama and user reporting of ADRs: Consumer intelligence matters in clinical practice and post-marketing drug surveillance

We systematically analysed two complementary samples of emails relating to patients' problems with the popular SSRI antidepressant, paroxetine. These mainly concerned serious mood disorders and drug withdrawal symptoms. 1,374 emails were immediate responses to a major BBC-TV documentary programme. These were contrasted with 862 messages on similar themes sent to a website discussion forum over a period of nearly three years. Despite the limitations of most individual email reports, we judged their collective weight to be profound. We also suggest that the value of "immersion" in a large body of such data may be greater than continuing exposure to a variable trickle of reports. We discuss the significance of these data in relation to the patient-prescriber relationship and pharmacovigilance. We suggest that the Internet offers unparalleled opportunities for soliciting and monitoring patients' reports of adverse drug reactions, and propose practical initiatives to capture peoples' experiences and thereby promote safer and more effective drug use.

[1] C Wilkinson,et al. Time to let the patient speak. , 1989, BMJ.

[2] Martin H. Teicher,et al. Antidepressant Drugs and the Emergence of Suicidal Tendencies , 1993, Drug safety.

[3] J. Krska,et al. Patient reporting of potential adverse drug reactions: a methodological study. , 2002, British journal of clinical pharmacology.

[4] K. Demyttenaere,et al. Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. , 2001, The Journal of clinical psychiatry.

[5] D. Black,et al. The abrupt discontinuation of fluvoxamine in patients with panic disorder. , 1993, The Journal of clinical psychiatry.

[6] A. Young,et al. Physicians' knowledge of antidepressant withdrawal effects: a survey. , 1997, The Journal of clinical psychiatry.

[7] A. Young,et al. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. , 1997 .

[8] M. Fava,et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial , 1998, Biological Psychiatry.

[9] P. Waller,et al. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. , 2003, British journal of clinical pharmacology.

[10] C. Medawar,et al. The Antidepressant WebMarketing depression and making medicines work. , 1997, The International journal of risk & safety in medicine.